1. Home
  2. ASMB vs KPTI Comparison

ASMB vs KPTI Comparison

Compare ASMB & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • KPTI
  • Stock Information
  • Founded
  • ASMB 2005
  • KPTI 2008
  • Country
  • ASMB United States
  • KPTI United States
  • Employees
  • ASMB N/A
  • KPTI N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • ASMB Health Care
  • KPTI Health Care
  • Exchange
  • ASMB Nasdaq
  • KPTI Nasdaq
  • Market Cap
  • ASMB 84.5M
  • KPTI 81.1M
  • IPO Year
  • ASMB 2010
  • KPTI 2013
  • Fundamental
  • Price
  • ASMB $13.42
  • KPTI $0.63
  • Analyst Decision
  • ASMB Buy
  • KPTI Strong Buy
  • Analyst Count
  • ASMB 2
  • KPTI 4
  • Target Price
  • ASMB $35.00
  • KPTI $5.00
  • AVG Volume (30 Days)
  • ASMB 22.6K
  • KPTI 694.6K
  • Earning Date
  • ASMB 03-27-2025
  • KPTI 02-27-2025
  • Dividend Yield
  • ASMB N/A
  • KPTI N/A
  • EPS Growth
  • ASMB N/A
  • KPTI N/A
  • EPS
  • ASMB N/A
  • KPTI N/A
  • Revenue
  • ASMB $28,326,000.00
  • KPTI $148,442,000.00
  • Revenue This Year
  • ASMB $282.16
  • KPTI $5.47
  • Revenue Next Year
  • ASMB N/A
  • KPTI $6.33
  • P/E Ratio
  • ASMB N/A
  • KPTI N/A
  • Revenue Growth
  • ASMB N/A
  • KPTI 1.77
  • 52 Week Low
  • ASMB $9.84
  • KPTI $0.58
  • 52 Week High
  • ASMB $19.93
  • KPTI $1.70
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 40.25
  • KPTI 46.51
  • Support Level
  • ASMB $13.60
  • KPTI $0.60
  • Resistance Level
  • ASMB $14.25
  • KPTI $0.70
  • Average True Range (ATR)
  • ASMB 0.58
  • KPTI 0.05
  • MACD
  • ASMB -0.05
  • KPTI -0.00
  • Stochastic Oscillator
  • ASMB 5.93
  • KPTI 46.61

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: